Abstract：
BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is a global health challenge, with a rising rate in line with other metabolic diseases. We aimed to assess the global prevalence of NAFLD in adult and pediatric populations.
METHODS: PubMed, Scopus and Web of Science databases were systematically searched up to May 2023. Heterogeneity was assessed using Cochran\'s Q test and I2 statistics, and random-effects model was used for meta-analysis. Analyses were performed using STATA version 18.
RESULTS: A total of 479 studies with 78,001,755 participants from 38 countries were finally included. The global prevalence of NAFLD was estimated to be 30.2% (95% CI: 28.7-31.7%). Regionally, the prevalence of NAFLD was as follows: Asia 30.9% (95% CI: 29.2-32.6%), Australia 16.1% (95% CI: 9.0-24.8%), Europe 30.2% (95% CI: 25.6-35.0%), North America 29% (95% CI: 25.8-32.3%), and South America 34% (95% CI: 16.9-53.5%). Countries with a higher human development index (HDI) had significantly lower prevalence of NAFLD (coefficient = -0.523, p = 0.005). Globally, the prevalence of NAFLD in men and women was 36.6% (95% CI: 34.7-38.4%) and 25.5% (95% CI: 23.9-27.1%), respectively. The prevalence of NAFLD in adults, adults with obesity, children, and children with obesity was 30.2% (95% CI: 28.8-31.7%), 57.5% (95% CI: 43.6-70.9%), 14.3% (95% CI: 10.3-18.8%), and 38.0% (95% CI: 31.5-44.7%), respectively.
CONCLUSIONS: The prevalence of NAFLD is remarkably high, particularly in countries with lower HDI. This substantial prevalence in both adults and children underscores the need for disease management protocols to reduce the burden.
METHODS: PubMed, Scopus and Web of Science databases were systematically searched up to May 2023. Heterogeneity was assessed using Cochran\'s Q test and I2 statistics, and random-effects model was used for meta-analysis. Analyses were performed using STATA version 18.
RESULTS: A total of 479 studies with 78,001,755 participants from 38 countries were finally included. The global prevalence of NAFLD was estimated to be 30.2% (95% CI: 28.7-31.7%). Regionally, the prevalence of NAFLD was as follows: Asia 30.9% (95% CI: 29.2-32.6%), Australia 16.1% (95% CI: 9.0-24.8%), Europe 30.2% (95% CI: 25.6-35.0%), North America 29% (95% CI: 25.8-32.3%), and South America 34% (95% CI: 16.9-53.5%). Countries with a higher human development index (HDI) had significantly lower prevalence of NAFLD (coefficient = -0.523, p = 0.005). Globally, the prevalence of NAFLD in men and women was 36.6% (95% CI: 34.7-38.4%) and 25.5% (95% CI: 23.9-27.1%), respectively. The prevalence of NAFLD in adults, adults with obesity, children, and children with obesity was 30.2% (95% CI: 28.8-31.7%), 57.5% (95% CI: 43.6-70.9%), 14.3% (95% CI: 10.3-18.8%), and 38.0% (95% CI: 31.5-44.7%), respectively.
CONCLUSIONS: The prevalence of NAFLD is remarkably high, particularly in countries with lower HDI. This substantial prevalence in both adults and children underscores the need for disease management protocols to reduce the burden.
摘要：
背景：非酒精性脂肪性肝病（NAFLD）是一个全球性的健康挑战，与其他代谢性疾病的发病率上升。我们旨在评估成人和儿童人群中NAFLD的全球患病率。
方法：PubMed，截至2023年5月，对Scopus和WebofScience数据库进行了系统搜索。使用CochranQ检验和I2统计量评估异质性，采用随机效应模型进行Meta分析。使用STATA版本18进行分析。
结果：最终纳入了来自38个国家的78,001,755名参与者的479项研究。NAFLD的全球患病率估计为30.2%(95%CI:28.7-31.7%)。区域,NAFLD的患病率如下：亚洲30.9%（95%CI：29.2-32.6%），澳大利亚16.1%（95%CI：9.0-24.8%），欧洲30.2%（95%CI：25.6-35.0%），北美29%（95%CI：25.8-32.3%），南美34%（95%CI：16.9-53.5%）。人类发展指数（HDI）较高的国家的NAFLD患病率明显较低（系数=-0.523，p=0.005）。全球范围内,男性和女性的NAFLD患病率分别为36.6%(95%CI:34.7-38.4%)和25.5%(95%CI:23.9-27.1%),分别。成人NAFLD的患病率，成人肥胖，孩子们,肥胖儿童为30.2%（95%CI：28.8-31.7%），57.5%（95%CI：43.6-70.9%），14.3%（95%CI：10.3-18.8%），和38.0%（95%CI：31.5-44.7%），分别。
结论：NAFLD的患病率非常高，特别是在人类发展指数较低的国家。这种在成人和儿童中的大量流行强调了疾病管理方案以减轻负担的必要性。
方法：PubMed，截至2023年5月，对Scopus和WebofScience数据库进行了系统搜索。使用CochranQ检验和I2统计量评估异质性，采用随机效应模型进行Meta分析。使用STATA版本18进行分析。
结果：最终纳入了来自38个国家的78,001,755名参与者的479项研究。NAFLD的全球患病率估计为30.2%(95%CI:28.7-31.7%)。区域,NAFLD的患病率如下：亚洲30.9%（95%CI：29.2-32.6%），澳大利亚16.1%（95%CI：9.0-24.8%），欧洲30.2%（95%CI：25.6-35.0%），北美29%（95%CI：25.8-32.3%），南美34%（95%CI：16.9-53.5%）。人类发展指数（HDI）较高的国家的NAFLD患病率明显较低（系数=-0.523，p=0.005）。全球范围内,男性和女性的NAFLD患病率分别为36.6%(95%CI:34.7-38.4%)和25.5%(95%CI:23.9-27.1%),分别。成人NAFLD的患病率，成人肥胖，孩子们,肥胖儿童为30.2%（95%CI：28.8-31.7%），57.5%（95%CI：43.6-70.9%），14.3%（95%CI：10.3-18.8%），和38.0%（95%CI：31.5-44.7%），分别。
结论：NAFLD的患病率非常高，特别是在人类发展指数较低的国家。这种在成人和儿童中的大量流行强调了疾病管理方案以减轻负担的必要性。
